Trials / Recruiting
RecruitingNCT06842498
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Kyntra Bio · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FG-3246 | FG-3246 will be administered per schedule specified in the arm description. |
Timeline
- Start date
- 2026-02-22
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
- First posted
- 2025-02-24
- Last updated
- 2026-03-20
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06842498. Inclusion in this directory is not an endorsement.